Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

This comes after both Maccabi and Meuhedet Health Services announced the same subsidy for the Mounjaro weight loss shot.

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

While GLP-1 medications like Ozempic and Wegovy have garnered significant attention ... affect multiple body systems ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

The biotech industry in 2024 was marked by some contradictions: Even as layoffs continued to rip through companies large and ...